Interpace Biosciences, Inc.
1.1000-0.04 (-3.51%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCPK · IDXG · USD
Key Stats
Market Cap
4.87MP/E (TTM)
-Basic EPS (TTM)
-0.31Dividend Yield
0%Recent Filings
8-K
Q2 revenue dips on PancraGEN loss
Interpace Biosciences reported Q2 2025 net revenue of $9.2 million, down 23% from $12.0 million a year ago, as PancraGEN reimbursement loss triggered $1.2 million in one-time charges and a shift to thyroid-only focus. Yet thyroid testing surged 25% to $8.7 million on 16% volume growth, driving record collections of $10.8 million. Adjusted EBITDA fell to $0.4 million. July revenue jumped 54% year-over-year.
10-Q
Q2 FY2025 results
Interpace Biosciences posted Q2 revenue of $9.2M, down 23% y/y from $12.0M, as Medicare's LCD L39365 ended coverage for PancraGEN testing effective May 2025, slashing topline momentum. Gross margin slipped to 57.1% from 64.8%, while operating expenses held steady at $5.7M but included $0.5M in severance from the ensuing workforce cuts. This flipped operations to a $0.5M loss, versus $2.6M profit last year; net loss hit $0.6M, or $(0.14) diluted EPS on 4.4M shares. YTD, revenue dipped 7% to $20.7M with $1.4M operating income, buoyed by $1.8M operating cash flow minus $0.2M capex for $1.6M FCF. Cash ended at $0.5M, with $1.9M Term Loan (8% rate, due Dec 2025) after $2.5M paydown. Restructuring absorbed the hit. Regulatory shifts remain a drag.
10-Q
Q1 FY2025 results
Interpace Biosciences posted solid Q1 results, with revenue climbing 13% year-over-year to $11.5 million on higher test volumes, while gross margins edged up to 64% from 62%. Operating income from continuing operations rose to $1.8 million, up 64% y/y, driving net income of $1.6 million and diluted EPS of $0.06—note the anti-dilution from convertible preferred stock converting 23.3 million shares into the denominator. Cash from operations hit $1.2 million, funding a $1.5 million debt paydown that trimmed the BroadOak term loan to $2.9 million principal (8% rate, due December 31, 2025). Yet PancraGEN®'s Medicare non-coverage, finalized April 24, 2025 under LCD L39365 for genetic oncology testing, triggered a restructuring plan with $0.5–0.6 million in Q2 severance to align costs. Liquidity holds: $1.2 million cash at quarter-end, sufficient for 12 months per management. Competition in diagnostics remains fierce.
8-K
Q1 revenue surges 13%
Interpace Biosciences reported Q1 2025 net revenue of $11.5 million, up 13% year-over-year, fueled by 19% growth in thyroid testing to $8.0 million and record cash collections of $11.3 million. Operating income rose to $1.8 million from $1.1 million, with Adjusted EBITDA at $2.1 million, reflecting efficiency gains from AI investments. The company initiated full-year revenue guidance of approximately $38 million, despite impending PancraGEN revenue loss after May 2. Solid cash flow strengthens the balance sheet.
8-K
PancraGEN reimbursement ends
Interpace Biosciences lost Medicare reimbursement for its PancraGEN test effective April 24, 2025, after a 60-day delay, halting acceptance of specimens post-May 2. The company activated its restructuring plan on April 25, slashing workforce and expecting $0.5-$0.6 million in Q2 severance costs atop $0.2 million already booked. This will trim annual costs by $12.5-$14.5 million, offsetting about one-third of lost revenues. Restructuring wraps by Q2 end, but actual costs may vary.
IPO
Website
Employees
Sector
Industry
APDN
Applied DNA Sciences, Inc.
5.62+1.35
BDSX
Biodesix, Inc.
6.54-0.01
CSTL
Castle Biosciences, Inc.
23.74-0.41
DGX
Quest Diagnostics Incorporated
174.78-3.50
IDXX
IDEXX Laboratories, Inc.
627.66-6.70
ILMN
Illumina, Inc.
95.03-2.77
IMDX
Insight Molecular Diagnostics I
5.91-0.31
MYGN
Myriad Genetics, Inc.
7.91-0.22
PSNL
Personalis, Inc.
9.55-0.20
WGS
GeneDx Holdings Corp.
131.76-5.71